Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

4D Molecular Therapeutics (FDMT) Liabilities and Shareholders Equity (2019 - 2025)

Historic Liabilities and Shareholders Equity for 4D Molecular Therapeutics (FDMT) over the last 7 years, with Q3 2025 value amounting to $424.0 million.

  • 4D Molecular Therapeutics' Liabilities and Shareholders Equity fell 2980.76% to $424.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.0 billion, marking a year-over-year decrease of 1003.63%. This contributed to the annual value of $560.4 million for FY2024, which is 6487.17% up from last year.
  • 4D Molecular Therapeutics' Liabilities and Shareholders Equity amounted to $424.0 million in Q3 2025, which was down 2980.76% from $473.6 million recorded in Q2 2025.
  • In the past 5 years, 4D Molecular Therapeutics' Liabilities and Shareholders Equity registered a high of $629.9 million during Q1 2024, and its lowest value of $240.6 million during Q3 2021.
  • Its 5-year average for Liabilities and Shareholders Equity is $390.3 million, with a median of $352.5 million in 2023.
  • Its Liabilities and Shareholders Equity has fluctuated over the past 5 years, first soared by 15812.7% in 2024, then tumbled by 2980.76% in 2025.
  • 4D Molecular Therapeutics' Liabilities and Shareholders Equity (Quarter) stood at $353.5 million in 2021, then fell by 25.92% to $261.8 million in 2022, then rose by 29.81% to $339.9 million in 2023, then soared by 64.87% to $560.4 million in 2024, then fell by 24.34% to $424.0 million in 2025.
  • Its last three reported values are $424.0 million in Q3 2025, $473.6 million for Q2 2025, and $515.7 million during Q1 2025.